ClinicalTrials.gg
CompletedNCT02517632PEACHUpdated Jul 27, 2017

Physical Exercise Program in Chronic Chagas Heart Disease

A Phase 3 interventional study of Exercise, nutritional and pharmaceutical counceling and Nutritional and pharmaceutical counceling in Chagas Disease and Chagas Cardiomyopathy, sponsored by Evandro Chagas National Institute of Infectious Disease. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-27.

Primary conditionChagas CardiomyopathyRegistry: Chagas DiseaseReclassifiedWhy we changed it
Registry
Chagas Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chagas Cardiomyopathy
Why
  1. The study's listed conditions name Chagas Cardiomyopathy, a narrower term within Chagas Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Evandro Chagas National Institute of Infectious Disease · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Mar 2015, registered Aug 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Chagas Cardiomyopathy with a site in Brazil — 2 open to participants now, 2 under way, 1 of them phase 3. Chagas Cardiomyopathy · Brazil.

Enrollment
9th of 11
30 · median 42
Started
2015
the only one that year
Phase 3
3 of 14
1 open now
Registered
9th of 14
by date
Lead sponsor
2 of 14
Evandro Chagas National Institute of Infectious Disease

Among the 14 studies in Chagas Cardiomyopathy with a site in Brazil, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 3, and was the 9th registered.

Chagas Cardiomyopathy

17 studies on the registry are indexed under Chagas Cardiomyopathy; 2 are open to participants now.

Browse Chagas Cardiomyopathy studies →

Open to participants now

2 of the 14 studies in Chagas Cardiomyopathy with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 2 Chagas Cardiomyopathy studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Chagas Cardiomyopathy with a site in Brazil, or all of them as a file.
02

Study summary

The aim of this investigation is to evaluate the impact of exercise in a cardiac rehabilitation program on functional capacity, clinical markers, quality of life and biomarkers in patients with chronic chagasic cardiomyopathy.

Read the detailed description

The present study consisted in a randomized clinical study conducted at the Evandro Chagas National Institute of Infectious Disease (INI), located on Rio de Janeiro, Brazil. INI is a national reference center for treatment and research in infectious diseases and tropical medicine in Brazil, which follows a large cohort of patients with Chagas disease, all of them diagnosed by two simultaneously positive serological tests (enzyme-linked immunosorbent assay and indirect immunofluorescence). Patients included in the study are randomly divided in two groups: intervention and control groups. Safety analysis will be performed by monitoring any symptoms presented during data collection and follow-up study.

One of the potential risks that the patient may experience during the study is a noninvasive test that will be performed on a treadmill in a controlled environment, with the possibility of the appearance of symptoms such as fatigue, dyspnea, chest pain, dizziness, with minimal chances of occurring complications of difficult clinical control. Except for the blood test and the cardiopulmonary exercise test, the other tests to be performed are non-invasive and do not bring any risk to the participant's health. Will be collect 10 ml of blood which will be stored for up to five years for biomarker assessments.

During the exercise sessions, patients will be clinically monitored for decompensation, need for hospitalization and suspend or end the participation on the study. All cases will be individually assessed to determine the reversibility of the clinical status. Those cases will continue to be followed by the assistant staff, offering all the clinical support available in INI.

03

Conditions studied

  • Chagas Disease
  • Chagas Cardiomyopathy

Browse trials for

Keywords

  • Physical activity
  • Cardiac rehabilitation
04

In context

Chagas Cardiomyopathy Reclassified

17 studies on the registry are indexed under Chagas Cardiomyopathy; 2 are open to participants now.

This study's enrollment of 30 is below the median of 45 across 13 interventional studies indexed under Chagas Cardiomyopathy.

Browse Chagas Cardiomyopathy studies →

Lead sponsor

Evandro Chagas National Institute of Infectious Disease is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within Chagas Cardiomyopathy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Chagas Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: (1) Chagas disease diagnosis by serology; (2) chronic chagasic cardiomyopathy, with \<45% or compensated heart failure (3) clinical stability in the last three months, (4) adherence to the ambulatory clinical treatment and (5) age above 18 years.

Exclusion Criteria: (1) pregnancy, (2) neuromuscular limitations, (3) tobacco use, (4) evidence of nonchagasic heart disease, (5) systemic conditions that limits exercise practice or hemodynamic stress tests (6) unavailability to attend three times a week for a minimum of six months, (7) practitioners of regular exercise and (8) claustrophobia.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Exercise group

    This arm will be submitted to a exercise session and counseling from pharmaceutical and nutritional professionals.

    Behavioral: Exercise, nutritional and pharmaceutical counceling

  • Other
    Control group

    This arm will have only the counseling from pharmaceutical and nutritional professionals.

    Behavioral: Nutritional and pharmaceutical counceling

Interventions

  • BehavioralExercise, nutritional and pharmaceutical counceling

    The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.

  • BehavioralNutritional and pharmaceutical counceling

    The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.

07

What researchers measure

Primary outcomes

  1. Functional capacity measured by peak exercise oxygen consumption

    This measure is taken during a maximal progressive cardiopulmonary exercise test.

    Time frame: Changes from baselint at three and six months

Secondary outcomes

  1. Muscle respiratory strength

    Maximal inspiratory pressure and maximal expiratory pressure (cmH2O)

    Time frame: Changes from baselint at three and six months

  2. Body composition (body fat percentage)

    Measurement of skinfold thickness were taken at the chest, midaxillary, triceps, subscapular, abdomen, suprailiac and thigh sites on the right side of the body while standing in a relaxed position. The sum of these seven skinfold thicknesses was used to estimate body composition by Jackson \& Pollock equation.

    Time frame: Changes from baselint at three and six months

  3. Cardiac function (maily ejection fraction)

    Meaured by echocardiography

    Time frame: Changes from baselint at three and six months

  4. Laboratorial biomarkers composite

    Total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol,triacylglycerol, glucose, glycated hemoglobin, inflammatory cytokines, Brain Natriuretic Peptide and components of oxidative stress.

    Time frame: Changes from baselint at three and six months

  5. Quality of life

    Minnesota Living with Heart Failure questionnaire (MLHFQ). Score ranging from 0 - 105.

    Time frame: Changes from baselint at three and six months

  6. 24 hours Holter

    Cardiac rhythm through continuous dynamic ECG

    Time frame: Changes from baselint at three and six months

  7. Nutritional assessment

    By semiquantitative food frequency questionnaire and 24-hour food intake recall.

    Time frame: Changes from baselint at three and six months

  8. Pharmaceutical assessment

    Semi-structured questionnaires, Morisky´s test, Naranjo Algorithm.

    Time frame: Changes from baselint at three and six months

  9. Microvascular reactivity

    Measured by laser speckle flowmetry

    Time frame: Changes from baselint at three and six months

  10. Body mass index

    Measured by the body weight (kg) divided by squared height (in meters).

    Time frame: Changes from baselint at three and six months

08

Study locations

1 site
  • Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation.
    Rio de Janeiro, 21040-360, Brazil
09

References and documents

Publications

  • Mendes Fde S, Sousa AS, Souza FC, Pinto VL, Silva PS, Saraiva RM, Xavier SS, Veloso HH, Holanda MT, Costa AR, Carneiro FM, Silva GM, Borges JP, Tibirica E, Pinheiro RO, Lara FA, Hasslocher-Moreno AM, Brasil PE, Mediano MF. Effect of physical exercise training in patients with Chagas heart disease: study protocol for a randomized controlled trial (PEACH study). Trials. 2016 Sep 2;17(1):433. doi: 10.1186/s13063-016-1553-4. PubMed 27590681 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Jan 2017, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2015
First posted
Aug 7, 2015
StartActual
Mar 2015
Primary completionActual
Jan 2017
CompletionActual
Jan 2017
Last update
Jul 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02517632
Lead sponsor
Evandro Chagas National Institute of Infectious Disease
Collaborators
National Institute of Cardiology, Laranjeiras, Brazil
Responsible party
Fernanda de Souza Nogueira Sardinha Mendes (Researcher, Evandro Chagas National Institute of Infectious Disease) — Principal investigator
First posted
Aug 7, 2015
Start date
Mar 2015
Primary completion
Jan 2017
Completion
Jan 2017
Last update
Jul 27, 2017

Study contacts

Fernanda Mendes, M.D.
principal investigator · Evandro Chagas National Institute of Infectious Disease

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion